Dr. Kirchmeier joined VBI in April of 2010. He comes to VBI from Merck Research Laboratories, where he was a Director in Bioanalytical and Formulation Sciences. During his initial tenure, he was responsible for biologics formulation and later worked on biochemical and biophysical characterization of vaccines, proteins and carbohydrates. Dr. Kirchmeier’s career has been very focused on biopharmaceutical formulation and delivery. Prior to VBI and Merck, he was a Scientist at Corixa Corporation, now GlaxoSmithKline, where he formulated monoclonal antibodies in addition to particulate and adenoviral vaccines. Prior to Corixa he was Director of Drug Delivery Research at Oakwood Laboratories, where his group was responsible for developing sustained-release formulations of peptides and proteins. Dr. Kirchmeier holds a Ph.D. in Chemistry from Oregon State University and a B.S. in Biochemistry from Western Washington University.